An interdisciplinary team, which includes scientists, engineers and physicians from Harvard University and the Institute of cancer research Dana-Farber announced the first phase of clinical trials of the experimental method melanoma therapy via implanted under the skin of the vaccine.
About the successful testing of a new method in mice with melanoma, the authors reported back in November 2009 in the journal Science Translational Medicine , and now intend to test the effectiveness and safety of mining on the people. Most current therapeutic cancer vaccines involve removing immune cells from the body, reprogram them to attack cancer cells and the introduction of the back. However, the effectiveness of such methods is small, as a large number of reprogrammed cells die.
Developed by a team from Harvard method allows not removing immune cells from the body. The tumor antigens adsorbed on a thin porous disk with a diameter of 8.5 mm from biologically inert, biorastvorimym plastic. The disc is implanted under the skin, after which dendritic cells that recognize antigens that penetrate the pores of the implant and receive information about tumor protein. They then transmit this information to other types of immune cells, which use it to recognize and destroy tumors.
Half of the mice that underwent the therapy with two doses of the vaccine, introduced a new method, instead of dying from skin cancer for 25 days, recovered. The methodology developed in relation to melanoma, but, according to the authors, can be applied to other types of cancer.
The set of participants of the first phase of clinical trials development, designed to evaluate its safety for people already started. It is expected that testing will be completed in 2015.